scispace - formally typeset
Open AccessJournal ArticleDOI

Fatty Acid Synthase and Cancer: New Application of an Old Pathway

Francis P. Kuhajda
- 15 Jun 2006 - 
- Vol. 66, Iss: 12, pp 5977-5980
Reads0
Chats0
TLDR
FAS is associated with poor prognosis in breast and prostate cancer, is elaborated into the blood of cancer patients, and its inhibition is selectively cytotoxic to human cancer cells.
Abstract
Fatty acid synthase (FAS), the sole mammalian enzyme capable of de novo fatty acid synthesis, is highly expressed in most human carcinomas. FAS is associated with poor prognosis in breast and prostate cancer, is elaborated into the blood of cancer patients, and its inhibition is selectively cytotoxic to human cancer cells. Thus, FAS and fatty acid metabolism in cancer has become a focus for the potential diagnosis and treatment of cancer.

read more

Citations
More filters
Journal ArticleDOI

Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis

TL;DR: FASN, a nearly-universal druggable target in many human carcinomas and their precursor lesions, offers new therapeutic opportunities for metabolically treating and preventing cancer.
Journal ArticleDOI

Lipid metabolic reprogramming in cancer cells

TL;DR: In it, detailed insight is provided into the essential roles exerted by specific lipids in mediating intracellular oncogenic signaling, endoplasmic reticulum stress and bidirectional crosstalk between cells of the tumor microenvironment and cancer cells.
Journal ArticleDOI

De novo Lipogenesis Protects Cancer Cells from Free Radicals and Chemotherapeutics by Promoting Membrane Lipid Saturation

TL;DR: Evidence is provided that shifting lipid acquisition from lipid uptake toward de novo lipogenesis dramatically changes membrane properties and protects cells from both endogenous and exogenous insults, and provides a rationale for the use of lipogenesis inhibitors as antineoplastic agents and as chemotherapeutic sensitizers.
Journal ArticleDOI

Fatty acid synthase as a potential therapeutic target in cancer

TL;DR: Overexpression of FASN is common in many cancers, and accumulating evidence suggests that it is a metabolic oncogene with an important role in tumor growth and survival, making it an attractive target for cancer therapy.
Journal ArticleDOI

Metformin in cancer therapy: a new perspective for an old antidiabetic drug?

TL;DR: There is increasing evidence of a potential efficacy of this agent as an anticancer drug, and several reports outline a direct inhibitory effect of metformin on cancer cell growth and an antitumoral action.
References
More filters
Journal ArticleDOI

The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.

TL;DR: Key developments of the last 20 years that have led to the current understanding of the physiology of the CPT system, the structure of theCPT isoforms, the chromosomal localization of their respective genes, and the identification of mutations in the human population are reviewed.
Journal ArticleDOI

Reduced Food Intake and Body Weight in Mice Treated with Fatty Acid Synthase Inhibitors

TL;DR: A link between anabolic energy metabolism and appetite control is identified and fatty acid synthase inhibitors may represent an important link in feeding regulation and may be a potential therapeutic target.
Journal ArticleDOI

Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.

TL;DR: This review documents the changing perspectives on the function of fatty-acid synthase and fatty- acid synthesis in human tumor biology and may provide new diagnostic and therapeutic moieties for patient care.
Journal ArticleDOI

Fatty acid synthesis: a potential selective target for antineoplastic therapy

TL;DR: Tumor cell lines with elevated fatty acid synthase showed commensurate increases in incorporation of [U-14C]acetate into acylglycerols demonstrating that fatty acids synthase increases occur in the context of overall increases in endogenous fatty acid synthesis.
Related Papers (5)